CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+6.21%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$907M
AUM Growth
+$907M
(+28%)
Cap. Flow
+$198M
Cap. Flow
% of AUM
21.86%
Top 10 Holdings %
Top 10 Hldgs %
37.32%
Holding
435
New
22
Increased
337
Reduced
40
Closed
7
Top Buys
| 1 |
Apple
AAPL
|
$25.8M |
| 2 |
Broadcom
AVGO
|
$24.2M |
| 3 |
Microsoft
MSFT
|
$10.9M |
| 4 |
Amgen
AMGN
|
$7.28M |
| 5 |
NVIDIA
NVDA
|
$6.87M |
Top Sells
| 1 |
Micron Technology
MU
|
$6.44M |
| 2 |
ServiceNow
NOW
|
$5.1M |
| 3 |
Salesforce
CRM
|
$5M |
| 4 |
CrowdStrike
CRWD
|
$4.33M |
| 5 |
Qualcomm
QCOM
|
$3.38M |
Sector Composition
| 1 | Technology | 37.6% |
| 2 | Healthcare | 28.11% |
| 3 | Consumer Discretionary | 12.57% |
| 4 | Communication Services | 9.53% |
| 5 | Consumer Staples | 3.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
Lexicon Pharmaceuticals
LXRX
$407M
| $109K | 0.01% |
69,527
+27,058
| +64% | +$42.5K |
|
352
4D Molecular Therapeutics
FDMT
$287M
| $108K | 0.01% |
9,995
+3,922
| +65% | +$42.4K |
|
|
THRD
353
DELISTED
Third Harmonic Bio
THRD
| $107K | 0.01% |
7,904
+3,092
| +64% | +$41.9K |
|
|
RVNC
354
DELISTED
Revance Therapeutics, Inc.
RVNC
| $105K | 0.01% |
20,161
+7,890
| +64% | +$40.9K |
|
355
UroGen Pharma
URGN
$904M
| $103K | 0.01% |
8,100
+3,856
| +91% | +$49K |
|
356
Regenxbio
RGNX
$461M
| $99.7K | 0.01% |
9,506
+3,720
| +64% | +$39K |
|
357
OmniAb
OABI
$227M
| $96.1K | 0.01% |
22,727
+8,909
| +64% | +$37.7K |
|
358
KalVista Pharmaceuticals
KALV
$719M
| $96K | 0.01% |
8,286
+3,328
| +67% | +$38.5K |
|
|
SLRN
359
DELISTED
ACELYRIN
SLRN
| $94.6K | 0.01% |
19,196
+7,560
| +65% | +$37.3K |
|
360
SIGA Technologies
SIGA
$618M
| $92.7K | 0.01% |
13,727
+5,372
| +64% | +$36.3K |
|
361
Anavex Life Sciences
AVXL
$814M
| $92.6K | 0.01% |
16,309
+6,366
| +64% | +$36.2K |
|
362
Pacific Biosciences
PACB
$384M
| $92.4K | 0.01% |
54,335
+20,417
| +60% | +$34.7K |
|
363
Prime Medicine
PRME
$556M
| $89.3K | 0.01% |
23,086
+8,985
| +64% | +$34.8K |
|
364
Phibro Animal Health
PAHC
$1.49B
| $88.1K | 0.01% |
3,912
+1,522
| +64% | +$34.3K |
|
365
Alector
ALEC
$262M
| $87.2K | 0.01% |
18,718
+7,395
| +65% | +$34.5K |
|
|
SAGE
366
DELISTED
Sage Therapeutics
SAGE
| $84.8K | 0.01% |
11,742
+4,672
| +66% | +$33.7K |
|
367
EyePoint Pharmaceuticals
EYPT
$809M
| $82.2K | 0.01% |
10,293
+4,172
| +68% | +$33.3K |
|
|
GRAL
368
GRAIL, Inc. Common Stock
GRAL
$1.14B
| $82.2K | 0.01% |
5,972
+2,670
| +81% | +$36.7K |
|
369
Xeris Biopharma Holdings
XERS
$1.28B
| $81.7K | 0.01% |
28,657
+11,239
| +65% | +$32K |
|
370
Taysha Gene Therapies
TSHA
$775M
| $79.2K | 0.01% |
39,417
+17,446
| +79% | +$35.1K |
|
|
VERV
371
DELISTED
Verve Therapeutics
VERV
| $78.8K | 0.01% |
16,276
+6,412
| +65% | +$31K |
|
372
MaxCyte
MXCT
$143M
| $78.6K | 0.01% |
20,212
+7,930
| +65% | +$30.8K |
|
373
Theravance Biopharma
TBPH
$697M
| $75.8K | 0.01% |
9,409
+3,696
| +65% | +$29.8K |
|
374
AC Immune
ACIU
$222M
| $71.9K | 0.01% |
19,021
+7,400
| +64% | +$28K |
|
375
iTeos Therapeutics
ITOS
| $71.7K | 0.01% |
7,024
+2,646
| +60% | +$27K |
|